PLN-101095 is under clinical development by Pliant Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PLN-101095’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PLN-101095 overview
PLN-101095 is under development for the treatment of solid tumor and pancreatic ductal adenocarcinoma. The drug candidate acts by targeting integrin alpha V beta 8 and integrin alpha V beta 1. It is administered through oral route.
Pliant Therapeutics overview
Pliant Therapeutics is a clinical-stage biopharmaceutical company that primarily focuses on the development of treatments for fibrotic diseases. The company’s pipeline products include PLN-74809, idiopathic pulmonary fibrosis (IPF); PLN-101095, primary sclerosing cholangitis (PSC); PLN-101325 and PLN-1474. Pliant Therapeutics’ products are primarily targeted towards patients suffering from fibrotic diseases and related conditions. Its therapies are designed to inhibit integrin-mediated activation of transforming growth factor beta (TGF-ß), a key driver in fibrosis. Pliant Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of PLN-101095’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
